Physician profile
Jayendra K Patel
NPI 1467434191
$12,522.29
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,407 · 2020: $4,806 · 2021: $909 · 2022: $335 · 2023: $50.57 · 2024: $16.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $9,981.70 | 2019-2023 | Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $538.07 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $416.42 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $389.42 | 2019-2023 | Invega Sustenna |
| Abbvie INC. | $354.06 | 2021-2022 | |
| Allergan, INC. | $164.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.53 | 2019-2021 | |
| Alkermes, INC. | $139.41 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $134.53 | 2019-2022 | |
| Lundbeck LLC | $67.23 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.18 | 2021 | |
| Acadia Pharmaceuticals INC | $37.67 | 2019 | |
| Merck Sharp & Dohme LLC | $28.71 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $25.69 | 2022 | |
| Lemaitre Vascular, INC. | $16.05 | 2024 | Artegraft Vascular Graft |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14.39 | 2021 | |
| Adlon Therapeutics L.P. | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.